CLOs on the Move

Genesis Therapeutics

www.genesistherapeutics.ai

 
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

9 Meters

9 Meters Biopharma is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS), larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease, and several near clinical-stage assets.

Advitech

Advitech is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharma-Bio Serv

Pharma-Bio Serv is a Plymouth Meeting, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Osage Bio Energy

Osage Bio Energy is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CytomX

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.